s an obscure disease. First identified as a multi-pigmented skin disease by a Hungarian doctor named Moritz Kaposi in 1872, it was considered to be quite rare--a medical curiosity usually found in particular populations such as older Italian men, transplant patients and young men in certain parts of sub-Saharan Africa. But then at the dawn of the AIDS pandemic in the early 1980s, the small purplish Kaposi's sarcoma skin lesions began appearing on the bodies of young American men, many of whom went on to develop opportunistic infections.

Dr. Berger became interested in KSHV because of his interest in how viruses enter cells. A decade ago, his research team was the first to identify CXCR4 as one of the coreceptors that allows HIV to gain entry into cells of the immune system. This discovery quickly led to the identification by Dr. Berger's group and several other research teams of CCR5 as the other HIV coreceptor.

By applying the same technology used to identify CXCR4, Drs. Kaleeba and Berger ultimately identified the protein xCT as the receptor that can make cells permissive for KSHV fusion.

The NIAID discovery may lead to new avenues for treating KSHV, says Dr. Berger. Moreover, their finding should enable scientists to determine whether levels of xCT determine disease severity. It also will allow researchers to study whether the expression of xCT on cells varies among different groups of people and whether these variations are genetic or environmental. This research may ultimately explain why certain groups are more at risk for Kaposi's sarcoma.

"Our finding provides a new perspective on the disease," says Dr. Kaleeba, who is originally from Uganda where Kaposi's sarcoma accounts for at least 10 percent of known tumors. "Hopefully this will be the beginning of exciting new directions in this field, as it is likely to provide a useful framework for integration of the cell biology and epidemiology of this clinically important virus."
'"/>

Contact: Jason Socrates Bardi
jbardi@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
6-Apr-2006

Page: 1 2 3
Related medicine news :

1. Landmark study finds adult Delawareans with disabilities in only fair to poor health
2. Landmark schizophrenia treatment study reveals that medication alone is not always effective
3. Landmark study of islet transplantation reveals potential benefits in uncontrolled type 1 diabetes
4. Landmark study on diabetic foot infection published
5. Landmark book commemorates centennial of discovery of Alzheimers disease
6. Landmark trial shows carotid stenting beneficial for patients with disease but no symptoms
7. Landmark hypertension study launches extensive physician and patient education program
8. Jefferson pharmacologist says biomarker discovery bodes well for better cancer diagnostics
9. Speeding fingertip discovery -- 20 years of protein info in 1 place
10. Major discovery raises prospect of better patient care by improving platelet life span
11. African scientists will train at Emory University in latest drug discovery techniques